Navigation Links
Reprogram stem cells with heart tissue, which might improve treatments for heart disease

This release is available in Spanish.

Spanish researchers have employed for the first time adult cells extracted from a human heart to turn stem cells from adipose tissue into cardiac myocytes. In other words, they achieved to "reprogram" adult stem cells, which might improve treatments for heart disease therapeutical.

At present, the use of stem cells in treatments for heart disease is one of the most common practices. However, working with stem cells without targeting heart tissue negatively affects the efficacy of treatments. Therefore, inducing cell differentiation into cardiac muscle (cardiomyocytes) may be one of the best options in the treatment of these pathologies.

For the purpose of this study, researchers isolated adult human stem cells from lipoaspiration. Subsequently, these cells were temporarily permeabilized and exposed to a human-auricle cell extract. Then, these cells were recovered in culture.

Morphological Changes

After 21 days in culture, the cells differentiated towards a cardiac myocyte phenotype, which was demonstrated by expression of morphological changes (appearance of binuclear cells with striated fibers and ramifications), detection of cardiospecific markers through inmunofluorescence, and the presence of cardiac muscle-related genes that were analysed through RT-PCR; and finally, by expression of reverse transcription. Thus, mesenchimal stem cells acquired a cardiac phenotype.

This study was conducted by Macarena Pern, Juan A. Marchal, Elena Lpez, Manuel Jimnez-Navarro, Houria Boulaiz, Fernando Rodrguez-Serrano, Esmeralda Carrillo, Gema Snchez-Espn, Eduardo de Teresa, David Tosh y Antonia Arnega, researchers from the University of Jaen (Spain), the University of Granada, the Hospital Clnico Universitario of Malaga and the University of Bath (United Kingdom). It is going to be published on the Journal Cytotherapy, the official reporting organ of the International Society for Cellular Therapy (ISCT).

This technique could be used in the future for regeneration of cardiac muscles through the use of cells directly extracted from the patient. However, physicians have remarked that, at present, this research is in its earlier stages, and it will be a long time until it has any therapeutical use.

Currently, researchers are preparing a new approach for introducing the cell extract into the target cell (by using a cell microinjector) that will allow them to obtain a larger number of viable differentiated cells, which is essential for their having any therapeutical use. The following step is to use animal models to validate differentiated cells' functionality. Finally, a number of clinical trials should be conducted to assess the viability of this technique in human patients.


Contact: Antonia Aranega Jimenez
University of Granada

Related biology news :

1. March of Dimes awards $250,000 prize to scientist who discovered how to reprogram human cells
2. Fate Therapeutics announces creation of small molecule platform for commercial-scale reprogramming
3. Tumor suppressor pulls double shift as reprogramming watchdog
4. Reprogramming human cells without inserting genes
5. Study reveals a reprogrammed role for the androgen receptor
6. Study finds blood cells can be reprogrammed to act as embryonic stem cells
7. Researchers piggyback to safer reprogrammed stem cells
8. Reprogrammable cell type depends on a single gene to keep its identity
9. Salk researchers successfully reprogram keratinocytes attached to a single hair
10. Yamanaka eliminates viral vector in stem cell reprogramming
11. Salk researchers reprogram adult stem cells in their natural environment
Post Your Comments:
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/22/2016)... , PROVO and ... -- Newborn Screening Ontario (NSO), which operates the highest ... for molecular testing, and Tute Genomics and UNIConnect, leaders ... technology respectively, today announced the launch of a project ... sequencing (NGS) testing panel. NSO has ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... Seattle, WA (PRWEB) , ... June 23, 2016 ... ... technology, announces the release of its second eBook, “Clinical Trials Patient Recruitment and ... patient recruitment and retention in this eBook by providing practical tips, tools, and ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
Breaking Biology Technology: